Go Pro
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free FBT Stock Alerts

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (FBT) Competitors

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation logo
GBX 2,331 -11.00 (-0.47%)
As of 07:19 AM Eastern
Compare

FBT vs. SOPH, PRSM, KAPE, TRST, and KNOS

Should you buy First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation stock or one of its competitors? MarketBeat compares First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation include Sophos Group plc (SOPH.L) (SOPH), Blue Prism Group (PRSM), Kape Technologies (KAPE), Trustpilot Group (TRST), and Kainos Group (KNOS). These companies are all part of the "software - application" industry.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Sophos Group plc (SOPH.L)?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) and Sophos Group plc (SOPH.L) (LON:SOPH) are both computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

In the previous week, First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's average media sentiment score of 0.00 equaled Sophos Group plc (SOPH.L)'saverage media sentiment score.

Company Overall Sentiment
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral
Sophos Group plc (SOPH.L) Neutral

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Sophos Group plc (SOPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A
Sophos Group plc (SOPH.L)£726.90M0.00N/A£1.70N/A

Company Net Margins Return on Equity Return on Assets
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/A N/A N/A
Sophos Group plc (SOPH.L) N/A N/A N/A

Summary

Sophos Group plc (SOPH.L) beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 3 of the 3 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Blue Prism Group?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) and Blue Prism Group (LON:PRSM) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

In the previous week, First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's average media sentiment score of 0.00 equaled Blue Prism Group'saverage media sentiment score.

Company Overall Sentiment
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral
Blue Prism Group Neutral

Company Net Margins Return on Equity Return on Assets
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/A N/A N/A
Blue Prism Group N/A N/A N/A

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Blue Prism Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A
Blue Prism Group£167.30M0.00N/A-£53.80N/A

Summary

Blue Prism Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 2 of the 3 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Kape Technologies?

Kape Technologies (LON:KAPE) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

Kape Technologies has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Kape Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kape Technologies£623.48M0.00£70.92M£0.15N/A
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

Kape Technologies has a net margin of 11.37% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Kape Technologies' return on equity of 6.97% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
Kape Technologies11.37% 6.97% 3.47%
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

Kape Technologies has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation has a beta of 0.4890005, indicating that its share price is 51% less volatile than the broader market.

11.4% of Kape Technologies shares are held by institutional investors. 81.1% of Kape Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Kape Technologies' average media sentiment score of 0.00 equaled First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation'saverage media sentiment score.

Company Overall Sentiment
Kape Technologies Neutral
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

Summary

Kape Technologies beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 9 of the 9 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Trustpilot Group?

Trustpilot Group (LON:TRST) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, Trustpilot Group had 2 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 2 mentions for Trustpilot Group and 0 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. Trustpilot Group's average media sentiment score of 0.56 beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's score of 0.00 indicating that Trustpilot Group is being referred to more favorably in the media.

Company Overall Sentiment
Trustpilot Group Positive
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

Trustpilot Group presently has a consensus target price of GBX 351.25, indicating a potential upside of 36.82%. Given Trustpilot Group's stronger consensus rating and higher probable upside, analysts plainly believe Trustpilot Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trustpilot Group
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Trustpilot Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Trustpilot Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trustpilot Group£261.05M3.80£20.08M£1.80142.63
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

Trustpilot Group has a net margin of 2.97% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Trustpilot Group's return on equity of 64.11% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
Trustpilot Group2.97% 64.11% 1.45%
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

Trustpilot Group has a beta of 0.507, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation has a beta of 0.4890005, suggesting that its stock price is 51% less volatile than the broader market.

42.7% of Trustpilot Group shares are owned by institutional investors. 13.5% of Trustpilot Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Trustpilot Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 14 of the 14 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Kainos Group?

Kainos Group (LON:KNOS) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Kainos Group presently has a consensus target price of GBX 1,173.40, suggesting a potential upside of 56.98%. Given Kainos Group's stronger consensus rating and higher probable upside, analysts clearly believe Kainos Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kainos Group
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Kainos Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Kainos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kainos Group£431.10M2.00£48.81M£35.1021.30
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

In the previous week, Kainos Group had 3 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 3 mentions for Kainos Group and 0 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. Kainos Group's average media sentiment score of 0.60 beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's score of 0.00 indicating that Kainos Group is being referred to more favorably in the media.

Company Overall Sentiment
Kainos Group Positive
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

36.8% of Kainos Group shares are held by institutional investors. 19.7% of Kainos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kainos Group has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation has a beta of 0.4890005, meaning that its share price is 51% less volatile than the broader market.

Kainos Group has a net margin of 9.86% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Kainos Group's return on equity of 41.45% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
Kainos Group9.86% 41.45% 14.45%
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

Summary

Kainos Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 14 of the 14 factors compared between the two stocks.

Get First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation News Delivered to You Automatically

Sign up to receive the latest news and ratings for FBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBT vs. The Competition

Export
MetricFirst Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationSoftware IndustryComputer SectorLON Exchange
Market Cap£956.21M£4.93B£38.13B£2.77B
Dividend YieldN/A4.07%3.18%6.15%
P/E Ratio-2,119.0926.3177.65369.54
Price / SalesN/A240.38601.2384,582.16
Price / Cash3.5417.5646.2327.87
Price / BookN/A4.259.447.63
Net IncomeN/A£22.26M£1.07B£5.89B
7 Day Performance1.75%-0.52%-2.62%-0.72%
1 Month Performance13.65%-1.37%-1.86%-1.26%
1 Year Performance58.65%-14.19%138.72%61.69%

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FBT
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
N/AGBX 2,331
-0.5%		N/A+60.5%£956.21MN/AN/A20
SOPH
Sophos Group plc (SOPH.L)
N/AN/AN/AN/A£2.99B£726.90M341.41520
PRSM
Blue Prism Group
N/AN/AN/AN/A£1.24B£167.30MN/A1,025
KAPE
Kape Technologies
N/AN/AN/AN/A£1.22B£623.48M1,900.00850
TRST
Trustpilot Group
3.9255 of 5 stars		GBX 271.80
-1.2%		GBX 351.25
+29.2%		+15.4%£1.05B£261.05M151.00820

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FBT) was last updated on 7/8/2026 by MarketBeat.com Staff.
From Our Partners
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
$2 an acre. They paid $412.
Government land listed at $2 an acre sold for $412 - 206 times asking price. Demand got so intense the feds do...
Behind the Markets | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
What Happens to Your Assets If You Die Without a Will?
About 55% of Americans have no will, trust, or estate planning document in place, leaving state intestacy law ...
SmartAsset | Sponsoredtc pixel
“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel